Sodium Sulfacetamide


Acella Pharmaceuticals, Llc
Human Prescription Drug
NDC 42192-146
Sodium Sulfacetamide is a human prescription drug labeled by 'Acella Pharmaceuticals, Llc'. National Drug Code (NDC) number for Sodium Sulfacetamide is 42192-146. This drug is available in dosage form of Gel. The names of the active, medicinal ingredients in Sodium Sulfacetamide drug includes Sulfacetamide Sodium - 100 mg/mL . The currest status of Sodium Sulfacetamide drug is Active.

Drug Information:

Drug NDC: 42192-146
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Sodium Sulfacetamide
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Sodium Sulfacetamide
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Acella Pharmaceuticals, Llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Gel
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:SULFACETAMIDE SODIUM - 100 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED DRUG OTHER
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 10 Oct, 2014
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 23 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Acella Pharmaceuticals, LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:1006107
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:4NRT660KJQ
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Sulfonamide Antibacterial [EPC]
Sulfonamides [CS]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
42192-146-12355 mL in 1 BOTTLE (42192-146-12)10 Oct, 2014N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Sodium sulfacetamide sodium sulfacetamide citric acid monohydrate cocamidopropyl betaine edetate disodium glycerin glyceryl monostearate methylparaben medium-chain triglycerides pentaerythrityl tetrastearate polysorbate 60 sodium lauryl sulfate sodium thiosulfate water xanthan gum sulfacetamide sodium sulfacetamide peg-60 almond glycerides peg-6 caprylic/capric glycerides peg-150 pentaerythrityl tetrastearate

Drug Interactions:

Drug interactions: sodium sulfacetamide 10% cleansing gel is incompatible with silver preparations.

Indications and Usage:

Indications and usage: sodium sulfacetamide 10% cleansing gel is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). it also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

Warnings:

Warnings: sulfonamides are known to cause stevens-johnson syndrome in hypersensitive individuals. stevens-johnson syndrome also has been reported following the use of sodium sulfacetamide topically. cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. in one of these cases, there was a fatal outcome. keep out of the reach of children.

Warnings and Cautions:

Precautions: for external use only. not for ophthalmic use. general: nonsusceptible organisms, including fungi, may proliferate with the use of this preparation. hypersensitivity reactions may recur when a sulfonamide is readministered, irrespective of the route of administration, and cross hypersensitivity between different sulfonamides may occur. if sodium sulfacetamide 10% cleansing gel produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed.

Dosage and Administration:

Dosage and administration: seborrheic dermatitis including seborrhea sicca - wash affected areas twice daily (morning and evening), or as directed by your physician. avoid contact with eyes or mucous membranes. wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly, pat dry and repeat after 10 to 20 seconds. rinsing with plain water will remove any excess medication. repeat application as described for 8 to 10 days. lf skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently. regular shampooing following sodium sulfacetamide 10% cleansing gel is not necessary, but the hair should be shampooed at least once a week. as the condition subsides, the interval between applications may be lengthened. applications once or twice weekly or every other week may prevent recurrence. should the condition recur after stopping therapy, the application of sodium sulfacetamide 10% cleansing gel sh
ould be reinitiated as at the beginning of treatment. secondary cutaneous bacterial infections - wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10 to 20 seconds working into a full lather, rinse thoroughly and pat dry. rinsing with plain water will remove any excess medication. repeat application as described for 8 to 10 days. if skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less often.

Contraindications:

Contraindications: sodium sulfacetamide 10% cleansing gel is contraindicated in persons with known or suspected hypersensitivity to sulfonamides or to any of the ingredients of the product.

Adverse Reactions:

Adverse reactions: reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. the following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of stevens-johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see warnings ). call your doctor for medical advice about side effects.

Drug Interactions:

Drug interactions: sodium sulfacetamide 10% cleansing gel is incompatible with silver preparations.

Use in Pregnancy:

Pregnancy: category c. animal reproduction studies have not been conducted with sodium sulfacetamide 10% cleansing gel. it is also not known whether sodium sulfacetamide 10% cleansing gel can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. sodium sulfacetamide 10% cleansing gel should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

Pediatric Use:

Pediatric use: safety and effectiveness in children under the age of 12 years has not been established.

Overdosage:

Overdosage: the oral ld50 of sulfacetamide in mice is 16.5 g/kg. in the event of overdosage, emergency treatment should be started immediately. to report suspected adverse reactions, contact the fda at 1-800-fda-1088 or www.fda.gov/medwatch. manifestations: overdosage may cause nausea and vomiting. large oral overdosage may cause hematuria, crystalluria and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. for treatment, contact your local poison control center or your doctor.

Description:

Description: each ml of sodium sulfacetamide 10% cleansing gel contains 100 mg of sodium sulfacetamide, usp in a formulation containing citric acid, cocamidopropyl betaine, disodium edta, glycerin, glyceryl stearate, methylparaben, peg-6 caprylic/capric glycerides, peg-60 almond glycerides, peg-150 pentaerythrityl tetrastearate, polysorbate 60, sodium lauryl sulfate, sodium thiosulfate, water, xanthan gum. sodium sulfacetamide is c 8 h 9 n 2 nao 3 s·h 2 o with molecular weight of 254.24. chemically, it is n-[(4-aminophenyl)sulfonyl]-acetamide, monosodium salt, monohydrate. the structural formula is: sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. it is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether. chemical structure

Clinical Pharmacology:

Clinical pharmacology: sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive gram-positive and gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. it acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. there is no clinical data available on the degree and rate of systemic absorption of sodium sulfacetamide 10% cleansing gel when applied to the skin or scalp. however, significant absorption of sodium sulfacetamide through the skin has been reported. the following in vitro data is available but the clinical significance is unknown. organisms that show susceptibility to sodium sulfacetamide are: streptococci, staphylococci, e. coli, klebsiella pneumoniae, pseudomonas pyocyanea, salmonella species, proteus vulgaris, nocardia and actinomyces.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis and impairment of fertility: long-term animal studies for carcinogenic potential have not been performed on sodium sulfacetamide 10% cleansing gel to date. studies on reproduction and fertility also have not been performed. chromosomal nondisjunction has been reported in the yeast, saccharomyces cerevisiae, following application of sodium sulfacetamide. the significance of this finding to the topical use of sodium sulfacetamide in the human is unknown.

How Supplied:

How supplied: sodium sulfacetamide 10% cleansing gel is available in a 12 fl. oz. (355 ml) bottle, ndc 42192-146-12.

Information for Patients:

Information for patients: patients should discontinue sodium sulfacetamide 10% cleansing gel if the condition becomes worse, or if a rash develops in the area being treated or elsewhere. sodium sulfacetamide 10% cleansing gel also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop.

Package Label Principal Display Panel:

Package label - 12 fl. oz. (355 ml) bottle ndc 42192-146-12 sodium sulfacetamide 10% cleansing gel rx only for external use only 12 fl. oz. (355 ml) acella pharmaceuticals, llc sodium


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.